论文部分内容阅读
乙型肝炎是严重危害公众健康的主要疾病之一,全世界慢性乙型肝炎病毒(HBV)感染者超过3.5亿人,而我国超过1.2亿人,其中约10％死于HBV持续感染后引起的肝硬化和肝癌。但是乙型病毒性肝炎目前还缺乏可靠的特效治疗,基本原则均以休息、合理饮食、避免饮酒和服用损害肝细胞的药物,药物治疗除一般的保肝药物(肝太乐、肌苷、维生素类)外,主要是抑制HBV的复制,目前主要有干扰素(IFN)和核苷类似物(拉米呋啶、泛昔洛韦)。近年来又提出免疫疗法及基因疗法等,但效果都未肯定。本文仅将目前临床最常用的干扰素治疗乙型病毒性肝炎的近况作一总结。
Hepatitis B is one of the major diseases that seriously endanger public health. More than 350 million people have chronic hepatitis B virus infection in the world, while more than 120 million people in our country die, about 10% of them died of persistent HBV infection Cirrhosis and liver cancer. However, the current lack of reliable special treatment of hepatitis B, the basic principles are to rest, a reasonable diet, to avoid drinking and taking drugs that damage liver cells, drug treatment in addition to the general liver drugs (liver too Le, inosine, vitamins Class), the main inhibition of HBV replication, the main interferon (IFN) and nucleoside analogues (lamivudine, famciclovir). In recent years, immunotherapy and gene therapy have been proposed, but the results are not yet confirmed. This article only the current clinical most commonly used interferon treatment of hepatitis B to make a summary of the status quo.